Seattle Genetics is a biotechnology company based in Seattle, Washington. The company focuses on the creation of ADC, antibody-based cancer therapies. So far, they have managed to get one of their drugs ADCETRIS, approved by the FDA. The co-founder and president of the company are Dr. Clay Siegall. Clay says that the corporation is in the process of getting 11 other drugs into their final testing stage, and there are hopes that they will be in use soon. The company is listed on NASDAQ in the name SGEN.
Clay says that he was inspired to go into research on antibody-based cancer therapies because of his father’s experience with cancer. When Clay was 19, his father was diagnosed with cancer. The next five years were very tough as his father fought cancer; unfortunately, he lost the battle when Clay was 24. Dr. Siegall says that he was made aware of the fact that it was not the severity of the tumor that hurt his father the most, but the therapies which were being used to deal with the disease at the time. This experience inspired him to create treatments which were antibody-based, and which would be more kind to the patient’s body in the long term.
He says that one of the things that have helped him get to the level of success he enjoys is his belief that he does not know enough. He recommends extensive learning and endless thirst for more information to anyone who wants to be a successful entrepreneur. He adds that when in business, it is important to form strategic business partnerships and collaborations. The company has been in partnership with Pfizer, GlaxoSmithKline, and Genentech. The ADC partnerships have helped them expand their research and achieve the current results. Their business partnership with Takeda Pharmaceuticals, the Canadian Company has helped them market their drugs all over the world.
Clay Siegall says that succeeding in business often comes after many years of hard work and setbacks. He admits that in the 20 years that he has been running Seattle Genetics, resilience has helped him achieve the current level of success.